Join our daily newsletter At The Bell to receive exclusive market insights
- Fiji Kava (FIJ) appoints healthcare wholesale company ANZ Pharma as its exclusive distributor in New Zealand
- As part of the agreement, ANZ Pharma will launch the Fiji Kava range of capsules and drinking kava in the New Zealand market
- The products will be stocked through retail channels such as supermarkets, tourism retail outlooks and petrol, route and convenience stops
- The contract includes a sales performance requirement of $1.1 which, if met, could extend the deal by another three years
- Shares in Fiji Kava are trading at 1.8 cents at 2:38 pm AEDT
Fiji Kava (FIJ) has appointed healthcare wholesale company ANZ Pharma as its exclusive distributor in New Zealand.
As part of the agreement, ANZ Pharma will launch the Fiji Kava range of capsules and drinking kava in the New Zealand market.
The products will be stocked through retail channels such as supermarkets, tourism retail outlooks and petrol, route and convenience stops.
The contract includes a sales performance requirement of $1.1 which, if met, could extend the deal by another three years.
“Alongside the Australian market, the New Zealand market has seen a big increase in demand for kava products over the last year,” Fiji Kava CEO Anthony Noble said.
“The team has worked hard to find the right partner, and working with a strong company like ANZ Pharma, who have a stable of national and multinational clients including Bondi Sands, Herbs of Gold, Unilever, Red Bull and Reckitt, gives us great confidence to re-enter this important market.”
ANZ Pharma Director Nitin Patel said the partnership was in alignment with the company’s long-term strategic goal of bringing high-quality products at great value to New Zealand consumers.
Shares in Fiji Kava were trading at 1.8 cents at 2:38 pm AEDT.
